News
AstraZeneca, Dizal Complete $1.5B Deal for Lung Cancer Drug Zegfrovy
Under the agreement, AstraZeneca has acquired worldwide rights to develop and commercialise Zegfrovy.
E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Under the agreement, AstraZeneca has acquired worldwide rights to develop and commercialise Zegfrovy.
HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
